Mepolizumab use and glucocorticoid-free remission in eosinophilic granulomatosis with polyangiitis

Objectives To identify clinical characteristics and treatment-related factors associated with glucocorticoid (GC)-free remission in eosinophilic granulomatosis with polyangiitis (EGPA). Methods We retrospectively analyzed patients with EGPA who were treated at our hospital between May 2005 and December 2025. GC-free remission was defined as maintaining a Birmingham Vasculitis Activity Score (BVAS) of 0 for at least 3 months after GC discontinuation. Factors associated with GC-free remission were evaluated using multivariable Cox regression, with mepolizumab (MEP) exposure treated as a time-dependent covariate. Patients who started MEP within one month of GC initiation or dose escalation were defined as the early MEP group. Results A total of 58 patients were included. Forty patients were women (68.9%), and 15 were MPO-ANCA positive (25.9%). Twenty-three patients (39.7%) received pulse GC therapy, and 35 (60.3%) received MEP. During follow-up, 23 patients (39.7%) achieved GC-free remission. MEP use was more frequent among patients who achieved GC-free remission (91.3% vs. 40.0%, p<0.01) and was independently associated with GC-free remission (HR 37.65, 95% CI 8.32–170.27; p<0.001). In patients who achieved GC-free remission, the mean time to remission was shorter in the early MEP group than in the non-early group (462 ± 227 vs. 723 ± 113 days, p = 0.03). Conclusion MEP use was independently associated with GC-free remission in EGPA. Among patients who achieved GC-free remission, earlier MEP initiation was associated with a shorter observed time to GC-free remission.

Authors

Institutions

Publication Details

Journal
Frontiers in Immunology
Published
2026-11-17
DOI
https://doi.org/10.3389/fimmu.2026.2003423
Primary Topic
Vasculitis and related conditions
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Mepolizumab use and glucocorticoid-free remission in eosinophilic granulomatosis with polyangiitis

Shoichi Yoshinaga, Hironari Hanaoka, Ryota Sakai, Akiko Shibata et al.
1 links
Frontiers in Immunology
Vasculitis and related conditions
article

Mepolizumab use and glucocorticoid-free remission in eosinophilic granulomatosis with polyangiitis

Shoichi Yoshinaga, Hironari Hanaoka, Ryota Sakai, Akiko Shibata, Takahiko Kurasawa, Taiji Kosaka, Yuri Sasaki
article en

Abstract

Objectives To identify clinical characteristics and treatment-related factors associated with glucocorticoid (GC)-free remission in eosinophilic granulomatosis with polyangiitis (EGPA). Methods We retrospectively analyzed patients with EGPA who were treated at our hospital between May 2005 and December 2025. GC-free remission was defined as maintaining a Birmingham Vasculitis Activity Score (BVAS) of 0 for at least 3 months after GC discontinuation. Factors associated with GC-free remission were evaluated using multivariable Cox regression, with mepolizumab (MEP) exposure treated as a time-dependent covariate. Patients who started MEP within one month of GC initiation or dose escalation were defined as the early MEP group. Results A total of 58 patients were included. Forty patients were women (68.9%), and 15 were MPO-ANCA positive (25.9%). Twenty-three patients (39.7%) received pulse GC therapy, and 35 (60.3%) received MEP. During follow-up, 23 patients (39.7%) achieved GC-free remission. MEP use was more frequent among patients who achieved GC-free remission (91.3% vs. 40.0%, p<0.01) and was independently associated with GC-free remission (HR 37.65, 95% CI 8.32–170.27; p<0.001). In patients who achieved GC-free remission, the mean time to remission was shorter in the early MEP group than in the non-early group (462 ± 227 vs. 723 ± 113 days, p = 0.03). Conclusion MEP use was independently associated with GC-free remission in EGPA. Among patients who achieved GC-free remission, earlier MEP initiation was associated with a shorter observed time to GC-free remission.

Frontiers in ImmunologyVol. 17
Saitama Medical Center, Saitama Medical University (JP)
Good health and well-being
Vasculitis and related conditions
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon